Medexus Pharmaceuticals Inc (TSE:MDP) has released an update.
Medexus Pharmaceuticals reported a revenue of $26.3 million for fiscal Q2 2025, with a notable increase in net income to $0.1 million, despite a decline in overall sales. The company’s financial discipline and improvements in manufacturing processes contributed to a rise in Adjusted EBITDA to $6.0 million, showcasing Medexus’s strategic efforts to strengthen its financial position.
For further insights into TSE:MDP stock, check out TipRanks’ Stock Analysis page.
